DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells
暂无分享,去创建一个
S. Zelenay | I. Melero | C. del Fresno | M. Krummel | D. Sancho | S. Mañes | M. Enamorado | S. Iborra | F. J. Cueto | M. Gómez | A. R. Sánchez-Paulete | Ruth Conde-Garrosa | A. Combes | Paola Brandi | Christian P. Bromley | Elena Hernández-García
[1] I. Melero,et al. Dendritic cells in cancer immunology and immunotherapy , 2019, Nature Reviews Immunology.
[2] M. Merad,et al. β-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma. , 2019, Cancer discovery.
[3] Chun Jimmie Ye,et al. Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity , 2019, Cell.
[4] M. Merad,et al. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination , 2019, Nature Medicine.
[5] Ralph Weissleder,et al. Successful Anti‐PD‐1 Cancer Immunotherapy Requires T Cell‐Dendritic Cell Crosstalk Involving the Cytokines IFN‐&ggr; and IL‐12 , 2018, Immunity.
[6] M. Diamond,et al. WDFY4 is required for cross-presentation in response to viral and tumor antigens , 2018, Science.
[7] A. Planas,et al. DNGR-1 in dendritic cells limits tissue damage by dampening neutrophil recruitment , 2018, Science.
[8] S. Asthana,et al. A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments , 2018, Nature Medicine.
[9] E. Sahai,et al. NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control , 2018, Cell.
[10] L. Zitvogel,et al. Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics , 2017, Oncoimmunology.
[11] M. Albert,et al. Critical role for Sec22b-dependent antigen cross-presentation in antitumor immunity , 2017, The Journal of experimental medicine.
[12] I. Melero,et al. Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8+ T cells , 2017, Nature Communications.
[13] T. Gajewski,et al. Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. , 2017, Cancer cell.
[14] Peisheng Zhang,et al. Resident memory T cells in the skin mediate durable immunity to melanoma , 2017, Science Immunology.
[15] J. Luke,et al. Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma , 2016, Proceedings of the National Academy of Sciences.
[16] C. del Fresno,et al. Optimal Generation of Tissue-Resident but Not Circulating Memory T Cells during Viral Infection Requires Crosspriming by DNGR-1+ Dendritic Cells. , 2016, Immunity.
[17] R. Reguera,et al. Leishmania Uses Mincle to Target an Inhibitory ITAM Signaling Pathway in Dendritic Cells that Dampens Adaptive Immunity to Infection. , 2016, Immunity.
[18] T. Kaisho,et al. Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma. , 2016, Cancer cell.
[19] F. Ginhoux,et al. Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. , 2016, Immunity.
[20] M. Koch,et al. Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients. , 2016, Cancer cell.
[21] María Martínez-López,et al. Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells. , 2016, Cancer discovery.
[22] Erik Sahai,et al. Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity , 2015, Cell.
[23] T. Gajewski,et al. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity , 2015, Nature.
[24] D. Sancho,et al. Batf3-dependent CD103+ dendritic cells are major producers of IL-12 that drive local Th1 immunity against Leishmania major infection in mice , 2014, European journal of immunology.
[25] Sebastian Amigorena,et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. , 2014, Cancer cell.
[26] Vivien W. Chan,et al. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. , 2014, Cancer cell.
[27] P. Bruhns,et al. Shifting FcγRIIA-ITAM from activation to inhibitory configuration ameliorates arthritis. , 2014, The Journal of clinical investigation.
[28] Shamim A. Mollah,et al. Classical Flt3L-dependent dendritic cells control immunity to protein vaccine , 2014, The Journal of experimental medicine.
[29] Joshua M. Stuart,et al. The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.
[30] S. Zelenay,et al. Genetic Tracing via DNGR-1 Expression History Defines Dendritic Cells as a Hematopoietic Lineage , 2013, Cell.
[31] J. Blanco,et al. Maraviroc, a CCR5 Antagonist, Prevents Development of Hepatocellular Carcinoma in a Mouse Model , 2013, PloS one.
[32] L. Akslen,et al. Tumor Necrosis Is a Prognostic Factor in Thick Cutaneous Melanoma , 2012, The American journal of surgical pathology.
[33] Ansuman T. Satpathy,et al. Cross-dressed CD8α+/CD103+ dendritic cells prime CD8+ T cells following vaccination , 2012, Proceedings of the National Academy of Sciences.
[34] Daigo Hashimoto,et al. Deciphering the transcriptional network of the DC lineage , 2012, Nature Immunology.
[35] Anna M. Keller,et al. The dendritic cell receptor DNGR-1 controls endocytic handling of necrotic cell antigens to favor cross-priming of CTLs in virus-infected mice. , 2012, The Journal of clinical investigation.
[36] M. Wright,et al. The dendritic cell receptor Clec9A binds damaged cells via exposed actin filaments. , 2012, Immunity.
[37] B. Thompson,et al. F-actin is an evolutionarily conserved damage-associated molecular pattern recognized by DNGR-1, a receptor for dead cells. , 2012, Immunity.
[38] Anna M. Keller,et al. Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8α+ dendritic cells , 2010, The Journal of experimental medicine.
[39] F. Ginhoux,et al. The origin and development of nonlymphoid tissue CD103+ DCs , 2009, The Journal of experimental medicine.
[40] M. Manz,et al. The concerted action of GM-CSF and Flt3-ligand on in vivo dendritic cell homeostasis. , 2009, Blood.
[41] N. Hacohen,et al. The small GTPase Rac2 controls phagosomal alkalinization and antigen crosspresentation selectively in CD8(+) dendritic cells. , 2009, Immunity.
[42] Anna M. Keller,et al. Identification of a dendritic cell receptor that couples sensing of necrosis to immunity , 2009, Nature.
[43] E. Unanue,et al. Batf3 Deficiency Reveals a Critical Role for CD8α+ Dendritic Cells in Cytotoxic T Cell Immunity , 2008, Science.
[44] D. Pennington,et al. Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. , 2008, The Journal of clinical investigation.
[45] Michael S Saag,et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1 , 2005, Nature Medicine.
[46] Mark M. Davis,et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[47] A. Gratwohl,et al. Flt3 ligand level reflects hematopoietic progenitor cell function in aplastic anemia and chemotherapy-induced bone marrow aplasia. , 1996, Blood.
[48] E. Maraskovsky,et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified , 1996, The Journal of experimental medicine.